The results of the MS-STAT2 trial (NCT03387670) were presented as a late-breaking abstract by Prof. Jeremy Chataway (University College London, UK) [1]. This study in SPMS patients was stimulated by the positive outcomes of the phase 2b MS-STAT trial (NCT00647348), which demonstrated a reduction of 43% in the mean rate of whole brain atrophy over 2 years in SPMS patients, with simvastatin 80 mg/day [2].
MS-STAT2 is a multicentre, randomised-controlled trial conducted at 31 hospital sites in the UK. Inclusion criteria were the same as in the MS-STAT trial. Participants had to be 25 to 65 years of age and have an Expanded Disability Status Scale (EDSS) score of 4.0 to 6.5. They had SPMS with steady progression rather than relapse as the major cause of increasing disability in the preceding 2 years. The participants were randomised to simvastatin 80 mg (40 mg in the first month) or matching placebo for up to 4.5 years. The primary outcome was confirmed disability progression (CDP).
The mean age of the 964 enrolled participants was 54 years, 73% were women, and the mean duration of MS was 23 years. Only 5% had had relapse activity in the previous year. Compliance was over 80%.
“There was no effect of simvastatin on the progression rate in this population of patients with progressing MS,” Prof. Chataway said. “The cumulative incidence of progression was around 40%.” The hazard ratio (HR) versus placebo was 1.13 (95% CI 0.91–1.31; P=0.26). A total of 365 progression events were confirmed.
Prof. Chataway summarised that the safety data was “excellent.” Many more (secondary) outcomes will be reported in the months to come, including analyses of patient-reported outcomes, biofluid markers, and MRI.
- Chataway J, et al. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2 trial): a multicentre, randomised, placebo-controlled, double-blind phase 3 clinical trial. Abstract O134, ECTRIMS 2024, 17–20 October 2024, Copenhagen, Denmark.
- Chataway J, et al. Lancet. 2014;383(9936):2213-21.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Gut microbiota modulates inflammation and cortical damage Next Article
Tolebrutinib slows disability worsening in relapsing MS »
« Gut microbiota modulates inflammation and cortical damage Next Article
Tolebrutinib slows disability worsening in relapsing MS »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Online First
Revised McDonald criteria allow earlier and more precise MS diagnosis
Blood markers predict MS progression
High depression genetic burden associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
First-line moderate-efficacy DMTs show similar efficacy
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Frexalimab shows favourable safety and efficacy in OLE
Transfer of ocrelizumab into breastmilk is negligible
Ineffective response to EBV in MS not seen in similar diseases
Encouraging real-world results of AHSCT to treat aggressive MS
Tolebrutinib slows disability worsening in relapsing MS
High-dose simvastatin does not slow disability progression in SPMS
Gut microbiota modulates inflammation and cortical damage
Related Articles
November 25, 2020
Modulating BTK-dependent inflammatory signalling in microglia
November 8, 2019
Tool to measure quality of life in MS
December 4, 2023
Rate of grey matter brain atrophy accelerates after menopause
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com